California in October became the latest state to reject a controversial bill designed to stop automatic substitution of brand-name biologics for interchangeable biosimilars. The bill, backed by innovator biotechs such as Amgen and Genentech, pushes for biosimilars to be defined as interchangeable by the US Food and Drug Administration before pharmacists can substitute them as a default practice. The legislation has failed to pass in 11 states.